Elutia (ELUT) vs Evaxion A/S (EVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Elutia (ELUT) has outperformed Evaxion A/S (EVAX) over the past year, losing 6.9% versus a loss of 51.5%. Over five years, ELUT leads with a -84.8% price change compared with -99.2% for EVAX. Elutia is the larger company by market cap ($36.6 million vs $27.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | EVAX |
|---|---|---|
| Share price | $0.8273 | $3.05 |
| Market cap | $36.64M | $27.52M |
| 1-day change | +0.88% | -2.87% |
| YTD return | +19.38% | -36.06% |
| 1-year return | -6.94% | -51.51% |
| 5-year return | -84.82% | -99.23% |
| EPS (TTM) | $-0.64 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.39 | $12.15 |
| 52-week low | $0.50 | $2.77 |
| Distance from 52-week high | -40.27% | -74.90% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +504.38% | +268.85% |
| Average volume | 185.82K | 200.14K |
| Shares outstanding | 44.29M | 9.02M |
| Employees | 25 | 46 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed EVAX by 44.6 percentage points over the past year.
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Healthcare · Medical Devices · 25 employees
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
ELUT vs EVAX FAQ
Which is bigger, Elutia or Evaxion A/S?
Elutia (ELUT) is larger, with a market capitalization of $36.64M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, ELUT or EVAX?
ELUT returned -6.94% over the past 12 months, compared with -51.51% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and Evaxion A/S in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Elutia and Biotechnology for Evaxion A/S.